You are here

Prophylactic cranial irradiation for patients with lung cancer

Péchoux, C.L., Sun, A., Slotman, B.J., (...), Belderbos, J., Gore, E.M.

THE LANCET Oncology, Volume 17, Issue 7, July 2016, Pages e277–e293

Commentary by Nir Peled

The practice of prophylactic cranial irradiation (PCI) is well established in limited SCLC and debated in extensive SCLC, while not recommended in NSCLC. Péchoux et al reviewed recently in The Lancet Oncology the literature to support this practice with a significant reduction of brain metastasis rate from ~50% to ~30% with a survival benefit of ~ 5% for 3 years in limited SCLC only. The survival benefit in extensive SCLC is still controversial.  PCI has moderate cognitive cost which increases over time, therefore current studies focus on neuroprotection while under PCI.

It is important to note that PCI stands for "prophylactic" while it is not really prophylactic, rather treat un-detectable brain disease. The studies that lead to this practice are quite old without an appropriate brain imagine on the primary assessment (e.g. no brain imagine or only brain CT). As SCLC responses very well to radiation, the current urgent UNMET need is to perform a randomized study to re-assess the role of PCI in comparison to WBRT only when required upon frequent brain MRIs in SCLC. There is no doubt that we may see higher rate of brain metastasis, however we may avoid un-necessary brain radiation to 50% of the patients and a delayed diagnosis may not affect overall survival outcome.

Till this will be proven, the current practice should stay upon the evidence provided.

Stay informed

Subscribe to our E-Alert to keep up to date with the new items in the Resource Centre

Made possible by an educational grant from

Please note that Lilly Oncology has no editorial control over the content of this Resource Centre. The Resource Centre and all content therein has been subjected to an independent editorial review.

Perspectives in Lung Cancer 2017

How I optimize treatment for my NSCLC patients with advanced and aggressive disease

Now available: Webcast on demand


ECCO 2017

Debating the optimal management in advanced and metastatic lung cancer: The right treatment for the right patient at the right time

Did you miss the Satellite Symposium?

Now available: Webcast on demand

This educational activity is provided by Elsevier. Independent sponsorship for this educational activity was provided by Lilly Oncology.

Interactive Case Reports

Read more about recent cases from the Journal of Thoracic Oncology. Test your knowledge and answer the questions following the case to get immediate feedback.